Gregory D. Gorgas has served as our President, Chief Executive Officer and on our board of directors since April 2017. He holds three decades of successful drug development and commercialization experience in both pharmaceutical corporations and biotech companies, including more than a dozen product launches, four of which were first-in-class. Before leading Artelo, Mr. Gorgas served as Senior Vice President, Commercial and corporate officer at Mast Therapeutics, a publicly held biotechnology company, where he had commercial leadership accountability and business development responsibilities for the hematology, oncology and cardiovascular programs. Prior to that, Mr. Gorgas worked at Biogen, a publicly held biotechnology company, as Senior Director, Global Marketing with responsibility for the strategic vision and operational commercialization of the company’s worldwide cancer business. Previously he held leadership positions of increasing responsibility with IDEC Pharmaceuticals, Chiron, Cetus and Upjohn, all publicly held companies. Mr. Gorgas currently serves as member of the board of directors at Theragence and on the advisory board of Klotho Therapeutics. Mr. Gorgas earned a BA in economics from California State University, Northridge and, from the University of Phoenix, an MBA.
Steven D. Reich, MD has served as our Chief Medical Officer since April 2018. Dr. Reich brought to Artelo over four decades of drug research experience, both as an academically based investigator for Phase I-III trials and as a senior leader in the biopharma industry where he designed and managed Phase I-IV trials. He has directed studies with sites in North America, Europe, and Asia. Dr. Reich’s managerial experience includes directing multinational medical research groups within pharmaceutical and biotechnology companies and at a contract research organization. He headed the clinical research programs which led to five US, one Canadian, and two European drug approvals, and he was a team member for multiple other international approvals, primarily anti-cancer drugs. Dr. Reich received his MD degree at the New Jersey College of Medicine and Dentistry and a diplomate certification from the American Board of Internal Medicine, with a sub-specialty of Medical Oncology. Dr. Reich was a clinical fellow at the Baltimore Cancer Research Center NCI, NIH, Baltimore, MD.
Jason Baybutt has been providing fractional CFO and accounting services to Artelo through his firm Pubco Reporting Solutions, Inc. since September 2014. Mr. Baybutt has over 15 years of experience providing C-level consulting and capital market advisory services with both private and public companies located in North America, Europe and Asia. In addition to financial, operational, and strategic advisory experience, his expertise includes the financial complexities associated with derivatives, reverse mergers, business combinations and acquisitions. Mr. Baybutt received his finance and accounting training at Mount Royal College in Calgary, Alberta, Canada.
Peter O’Brien has been head of our European operations since April 2017. As co-founder of Artelo Biosciences, he brought an accomplished record of creating, leading and selling multiple businesses including Medical Staff Ireland (sold in 2017), Nursing Station (acquired by Medacs Healthcare under the Impellam Group Plc in 2016) and Driver and Labour Recruit (sold in 2006). Mr. O’Brien also co-founded SPR Global Technologies which was acquired in 2018. Previously, he was a specialist in the private client sector at HSBC International in Jersey, Channel Islands, UK. Mr. O’Brien graduated from Griffith College, Cork, Ireland in 2004 with a concentration in Marketing, Sales, Public Relations and Advertising.
Randy Schreckhise joined Artelo in January 2020 serving as Vice President, Finance and Operations. He has made contributions to a number of approved therapeutics and therapeutic candidates through finance, business development, operations and strategy roles at aTyr Pharma, Abilita Bio, Trius Therapeutics, Ardea Biosciences, Human Genome Sciences and ZymoGenetics, and also through work in project management, protein biochemistry and genetics duri